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Abstract:  The aim of this work was to evaluate the efficiency and duration of gene 
expression mediated by a VSV-G pseudotyped last generation lentiviral (LV) vector. We 
studied LV efficiency in ex-vivo models of respiratory epithelial cells, obtained from 
bronchial biopsies and nasal polyps, by GFP epifluorescence and cytofluorimetry. In vivo 
efficiency and persistence of gene expression was investigated by GFP 
immunohistochemistry and luciferase activity in lung cryosections and homogenates, 
respectively, upon intranasal and intratracheal administration protocols in C57Bl/6 mice. 
Both primary bronchial and nasal epithelial cells were transduced up to 70-80% 72 hr after 
the LV infection. In vivo nasal luciferase expression was increased by 
lysophosphatidylcholine pre-treatment of the nose. Conversely, the bronchial epithelium 
was transduced in the absence of any pre-conditioning treatment and luciferase expression 
lasted for at least 6 months without any decline. We conclude that a last generation LV 




vector is a promising gene transfer agent in the target organ of genetic and acquired lung 
diseases, as in the case of cystic fibrosis. 
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1. Introduction 
Cystic Fibrosis (CF) is the most common life-shortening autosomal recessive disorder in Caucasian 
populations and its clinical symptoms are the consequence of mutations in the CF transmembrane 
conductance regulator (CFTR) gene on chromosome 7. CF is a chronic disease which requires gene 
delivery systems ensuring persistence of trangene expression. Early phase clinical trials have 
demonstrated that adenoviral and adeno-associated viral vectors could not achieve sustained CFTR 
expression and obtain clinical benefit [1]. HIV-1 derived lentiviral (LV) vectors are integrating vectors 
and considered a promising approach for CF gene therapy since they not only integrate in the host 
genome and ensure long-lasting expression of the therapeutic protein but also transduce quiescent cells 
and have been proved to be high efficient in the murine airway tract and achieve correction of the 
electrophysiological defect in the nose of CF mice [2]. Most of the studies on HIV-1-derived lentiviral 
mediated gene transfer in the airway epithelium refer to gene delivery mediated by LV vectors 
pseudotyped with vesicular stomatitis virus glycoprotein G (VSV-G) which is useful not only to allow 
virus particle concentration, but also to modulate virus interaction with the host immune system and to 
broaden its host range. However, VSV-G LV vectors have been shown to be inefficient in in vivo gene 
transfer into a fully differentiated epithelium [3-6] unless disruption of the epithelial barrier integrity 
obtained with calcium-chelating agents like EGTA [6], inhalation exposure to sulfur dioxide [3], or 
modification of the barrier function of the airway epithelium with lysophosphatidylcholine (LPC) [2] 
is obtained.  
In this study we evaluated the efficiency of a HIV-1-derived last generation LV vector in ex-vivo 
and in vivo models of airway epithelium: primary bronchial and nasal respiratory epithelial cells, and 
the murine airway epithelium. Our results show an unpredictable high transduction of the distal 
respiratory epithelium in vivo in the absence of preconditioning and persistence of gene expression. 
2. Results and Discussion 
In our laboratory, primary cultures of respiratory epithelial cells from bronchial biopsies and nasal 
polyps have been established [7-9]. Primary cells were transduced with MOIs (indicating viral 
particle:cell ratios) of 100 and 500. Confluent bronchial epithelial cells expressed GFP in a dose-
dependent fashion (Figure 1a-d). Cytofluorimetric analysis showed that the percentage of GFP-
positive cells was 54.4±4.4 and 82.5±2%, with 100 and 500 MOI respectively. Nasal epithelial cells 
grew more sparsely than bronchial cells, but showed high levels of GFP expression with LV infection 




cytofluorimetry. Overall, primary human respiratory epithelial cells demonstrated to be transduced  
ex-vivo by a last generation LV vector. 
Figure 1. GFP expression in human bronchial and nasal epithelial cells following LV 
infection. Bronchial cells were infected with 100 (a, b) or 500 (c, d) MOI. Nasal cells were 
infected with 500 MOI (e, f). GFP expression was evaluated 72 hr later. (a, c, e) Bright 
fields. (b, d, f) Epifluorescence of the same fields. Original magnification: 40X (a, b, c, d); 
63X (e, f). 
 
 
Transduction of the airway epithelium by VSV-G psudotyped LV vectors is not efficient because of 




LV vector used in this study is superior in efficiency as compared to prior versions in different models 
of primary cells [11]. Furthermore, we have previously shown that this LV vector is able to transduce 
polarized bronchial epithelial cells from the apical side, with an efficiency up to 65% [12]. Thus, the 
high transduction rates obtained with the last generation LV vector in primary human airway epithelial 
cells was promising for obtaining a good transduction of the respiratory epithelium in vivo. We 
preliminarly reported that the VSV-G pseudotyped LV vector used in this study transduced the murine 
bronchial/bronchiolar epithelium following an intratracheal injection [13]. To corroborate and deepen 
these data we studied the transduction of the airway epithelium in the respiratory tract of the mouse by 
comparing two delivery methods, i.e. intranasal vs. intratracheal instillation. 
Transduction of nasal epithelial cells by LV vectors is not achieved unless preconditioning of the 
upper airways is performed [2,14,15]. Since the LV vector was found to be very efficient in primary 
nasal epithelial cells (Figure 1e and f), the potential to transduce the nasal epithelium was attempted in 
the absence of any prior treatment. Luciferase activity in the nose homogenates was at the background 
value 1 week after instillation of 1x10
7 transducing units (TU) (Figure 2a). We then used LPC, a 
naturally occurring airway surfactant that has previously been shown to increase in vivo airway gene 
transduction in the nose [2,16]. In noses pre-treated with 1% LPC, the level of luciferase activity 
measured one week after gene delivery was 3.02.3x10
4 Relative Light Units (RLU) per microgram of 
protein (Figure 2a). These luciferase levels differed significantly from those achieved in the absence of 
pre-treatment. One month post-instillation, luciferase activity was 1.10.8 x10
3 and 1.40.5x10
4 in 
PBS- and LPC-pre-treated animals, respectively (Figure 2a). Although a clear difference is noted, this 
did not reach statistical significance, due to high luciferase levels reached in 7 out of 11 of PBS-pre-
treated mice. These results indicate that VSV-G LV mediated gene transfer in the nasal epithelium is 
enhanced by LPC pre-treatment, ensuring persistence of gene expression at least for one month post 
infection. Previous studies have shown that LPC preconditioning allows a VSV-G pseudotyped LV 
vector to transduce the respiratory epithelium, as well as the transitional epithelium [16,17]. 
Since the target lung anatomical district for CF gene therapy is represented by the lower respiratory 
tract, an intratracheal injection protocol already in use in our laboratory for nonviral vectors [9,18] was 
used for LV application to the lung. A dose of lentivirus corresponding to 1x10
7 TU was injected in 
the trachea of C57BL/6 mice and different time points after LV administration mice were sacrificed 
and lungs removed. GFP immunohistochemistry revealed that transduction was achieved in the 
bronchial epithelial cells at 1 month post-injection (Figure 3). Microscopic observation of sections 
stained with hematoxylin and eosin did not reveal any sign of tissue damage in LV treated lungs (not 
shown). 
To evaluate long-term transduction of the respiratory epithelium in the lung, we injected 1x10
7 TU 
of a LV vector expressing firefly luciferase. Measurement of luciferase activity in lung homogenates 
showed levels of 8.22.9x10
4 and 9.31.9x10
4 RLU per microgram of lung protein, one week and one 
month after gene delivery, respectively (Figure 2b). High levels of luciferase expression persisted for 
three and six months post injection, with measurements of 5.45.1 x10
4 and 1.61.3x10
5 RLU per 
microgram of lung protein, respectively.  
In the present study we have demonstrated that a last generation VSV-G pseudotyped LV vector 
can mediate efficient and sustained gene expression in the mouse airways. This result is concordant 




[12] and in primary cultures of human respiratory cells (this study). However, the high efficient and 
persistent transduction of the murine distal airways was at odds with some previous findings. Others 
have reported that the nasal epithelium needs to be pre-conditioned before applying the LV vector 
[2,16,17]. Although VSV-G pseudotyped vectors are unable to transduce the airway epithelium in 
differentiated xenograft model [4] and in vivo when administered via tracheal injection [3,6], in other 
studies VSV-G pseudotyped HIV vectors can transduce the alveolar epithelium [19,20] and conducting 
airway epithelium [21,22] in the absence of tight-junction disruption agents. The LV vector that we 
have used here has some advantages over the previous versions of HIV-1 lentiviral vectors, since two 
sequences, the PPT (PolyPurine Tract) and the WPRE (Woodchuck Post-Transcriprional Regulatory 
Elements) have been added to the viral genome to improve nuclear translocation and transduction 
efficiency [11]. Differences in LV efficiency in the lung and nose could be explained by different 
retention time in the two compartments [23]. Alternatively, differences in distribution of viral 
receptors or in intracellular processing of viral particles could account for different rate of transduction 
observed in the murine bronchial and nasal epithelium. Also the modality of virus administration could 
influence transduction outcomes, since intratracheal injection could generate a pressure in the lung, 
leading to the transient modification of the cellular permeability. 
In this study we have shown that the LV-mediated transduction in vivo lasts for at least 6 months by 
luciferase expression. Since the whole lung is assayed, it could be that most of the luciferase 
expression is from transduced alveolar cells, which vastly outnumber airway epithelial cells. This 
notion is given credence by the work of Borok et al. [24], which suggested that alveolar cells are 
apically much more amenable to VSV-G-LV transduction than airway epithelial cells. It is thus 
possible that only alveolar expression persists for 6 months since the bronchial epithelium expression 
was not examined any later than the 4-week timepoint. 
In a recent work [17], a VSV-G pseudotyped LV carrying LacZ or CFTR gene was delivered in the 
nostrils of mice 1 hour after pre-treatment with 0.3% LPC via inhalation-driven instillation. LacZ 
transgene expression lasted over 24 months and was restricted to the anterior regions of transitional 
and respiratory epithelium within the dosed nasal airway affecting primarily ciliated and nonciliated 
cells, but also a low number of secretory and basal cells. At 24 months when LacZ gene expression 
was still present, the number of cells transduced was significantly reduced compared to the initial  
1-week level. Significant correction of CFTR function, measuring nasal potential, was present at 1 and 
12 months compared to untreated mice. Although these findings are consistent with an approximate  
3-month cell turnover time originally established for murine tracheal airway [25], recent data suggest 
longer turnover times (up to 17 months) in deeper regions of the mouse lung [26].Thus, it is currently 
unclear, if prolonged expression is due to vector integration into the pulmonary stem or progenitor 
cells or due to the long life-expectancy of airway epithelial cells. It is possible that gene expression is 
maintained during time despite its lowering due to cell turnover and nonetheless persistence in a 
stem/progenitor niche due to a transient augmentation of paracellular permeability and allowance of 
LV vector to deeper cell layers. The development of this vector and its derivatives in the therapy of CF 
lung disease merit further research in its interaction with receptors and post-entry block mechanisms in 
basal cells and other progenitor cells of the respiratory epithelium.  




Figure 2. Luciferase expression in the murine airways following intranasal (a) or 
intratracheal (b) injection. (a) 1% LPC in PBS or PBS were instilled drop-wise in one 
nostril. One hour after, mice received a dose of 1x10
7 TU in 20 µl of PBS of the LV-Luc 
vector that was administered drop-wise to the same nostril. Mice were sacrificed one week 
(1 w) and four weeks (4 w) after gene transfer. The nose was dissected, homogenized, and 
evaluated for luciferase expression. n = 4-11 mice per group. (b) The LV-luc vector was 
administered to the lung via the trachea and mice were sacrificed 1, 4, 12, and 24 weeks 
after injection. The lung was removed, homogenized, and evaluated for luciferase 
expression. n = 5-10 mice per group. *p = 0.02 (unpaired Student’s t-test). 




Figure 3. GFP expression in bronchial epithelium of mice infected with the LV vector. 
PBS (a) or the LV-GFP vector (b) was injected in the lung of C57BL/6 mice through an 
intratracheal instillation. GFP expression was evaluated 1 month later by 
immunohistochemistry. Black arrows indicate areas of transduced airway epithelial cells. 
Note the absence of staining in the PBS-injected mice. Pictures are representative of three 
mice per group. Original magnification: X40. 
 




Detailed  studies are necessary to address whether lentivirus-based vectors can be considered 
immunologically safe for gene therapy of CF. Limberis and colleagues [19] have demonstrated that 
transient expression of Green Fluorescent Protein (GFP) at day 90 in alveolar epithelium following an 
intratracheal injection of VSV-G-pseudotyped HIV-1-derived vector to the mouse lung is due to 
transgene- and gag-specific T-cell activation. However, preliminary results obtained by our group 
indicate that this last generation LV vector does not elicit a pro-inflammatory response in human 
respiratory epithelial cells in vitro [27]. Furthermore, we have observed that the LV vector does not 
induce a strong immune response in the lung, as demonstrated by absence of CD4+ and CD8+ 
lymphocyte infiltrates in the bronchi/bronchioli of mice intratracheally injected [28]. 
3. Experimental Section 
Production of lentiviral vectors - The self-inactivating pRRLsin.cPPT.CMV.GFP.Wpre and 
pRRL.sin.PPT.CMV.luciferase.iresEMCVwtGFP.pre constructs (generously donated by Luigi Naldini, 
TIGET, H.S. Raffaele, Milan, Italy) were used to generate vesicular stomatitis virus glycoprotein 
(VSV-G)-pseudotyped LV vector stocks (LV-GFP and LV-luc, respectively) as described [11,29]. The 
yield of the concentrated virus was typically 10
8-10
10 TU/ml and the specific activity ranged between 
1.56 and 4.17x10
5 TU/ng of p24 Gag. 
Epithelial cell culture - Primary respiratory epithelial cells were derived by enzymatic digestion 
with type XIV Protease (Sigma Chemical, St. Louis, MO) from bronchial specimens obtained from 
surgical resection, as previously described [9]. Bronchial cells were seeded on rat tail collagen and 
cultured in RPMI/LHC9 (1:1), 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin.  
Respiratory epithelial cells were cultured from nasal polyps, as already described [7,8]. Briefly, 
explants (1–2 mm
2 in size) of human nasal polyps were seeded onto 60-mm tissue culture dishes 
coated with type I collagen associated with carbodiimide (Sigma, St. Louis, MO). Explants were then 
incubated in serum-free RPMI-1640 culture medium in the presence of 2 mM l-glutamine, 1 mg/ml 
insulin, 1 mg/ml transferrin, 10 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 10 ng/ml 
retinoic acid, 100 U/ml penicillin, and 100 g/ml streptomycin. Epithelial cells obtained from 
outgrowths of nasal polyps and bronchial specimens were trypsinized and cells were plated on 24-well 
plates at the density of 100,000 cells/well in 1 ml of culture medium.  
Transduction of epithelial cells - Cells were incubated with the vector in complete medium for 24 
hours containing the LV particles. The lentivirus was removed, cells washed with PBS, incubated in 
complete medium and evaluated for GFP expression after 48 hours by epifluorescence using a Zeiss 
Axiovert 135 microscope equipped with GFP filter (excitation 395 nm, emission 509 nm). 
Cytofluorimetry was performed with a FACScan apparatus (Becton-Dickinson, San Jose, CA) at 525 
nm. The percentage of GFP-positive cells was determined after setting the gating on 99% of an 
untransfected control population of cells and by substracting the fluorescence of the untransfected 
control cells. Ten thousand cells were examined in each experiment. Analysis of GFP production was 
performed by plotting the GFP channel (FL1) against the FL3 channel. Data are shown as the mean 
and standard deviations obtained from three experiments each for bronchial and nasal cells. 
In vivo experiments - All animals procedures were conformed to the requirements of the H. S. 




weight) were obtained from Charles River, Calco, Italy. For intranasal injection, mice were 
anesthetized with 12 mg/g body weight of Avertin and kept upright by hanging them by their teeth. 
Four µl of a solution of 1% LPC in PBS or PBS were instilled drop-wise in the nostril. Fourty-five 
minutes after, mice received 12 mg/g body weight of Avertin and a 15 minutes later a dose of 1x10
7 
TU of the LV-luc vector in 20 µl of PBS was administered drop-wise to the same nostril. Mice were 
sacrificed one week and one month after gene transfer. Nose was dissected and homogenized with a 
glass mortar and pestel in 1.5 ml of lysis buffer (25 mM Tris\HCl, 2 mM DTT, 2 mM EDTA, 10% 
Glycerol, 1% Triton X-100, pH = 8) on ice, homogenates were frozen in liquid nitrogen and thawed on 
ice and centrifuged at 12000 xg at 4 °C for 20 min. Fifty l of the supernatant were diluted with 100 l 
of water and assayed for luciferase activity in a Lumat LB 9507 instrument (Berthold, Bad Wildbach, 
Germany) by adding 100 l luciferase reagent (Promega) to each sample and measuring the light 
emitted over a 30 s period. Protein content of each sample was determined by a standard Lowry 
modified assay (Pierce) and the results expressed as relative light units (RLU) per g protein. Noses 
from mice injected with PBS only gave consistently those which are considered background levels  
(< 200 RLU/g protein). 
The LV vector was administered to the lung via the trachea as previously described [9]. The vector 
was administered through the catheter with a Hamilton syringe at the dose of 1x10
7 TU in 100 l of 
PBS. Control mice were injected with 100 l of PBS. Mice were sacrificed by cervical dislocation one 
weeks, one month, three and six months after transduction. For GFP immunodetection, lungs were 
removed and fixed in 4% paraformaldehyde and frozen; cryosections were stained with an antibody 
raised against GFP, as previously described [30]. Sections were observed at the Zeiss Axioplan-2 
epifluorescent microscope. To determine the luciferase activity, the lung was dissected out, washed in 
ice-cold PBS and immediately stored in 10 ml of ice-cold PBS. The homogenization of the samples 
was performed in 1 ml of lysis buffer (25 mM Tris\HCl, 2 mM DTT, 2 mM EDTA, 10% Glycerol, 1% 
Triton X-100, pH = 8) using an Ultraturrax Homogenizer at the maximum speed for 40 s. Samples 
were frozen in liquid nitrogen, allowed to thaw on ice and then centrifuged at 12000 xg at 4 °C for 
20 min. Luciferase activity was determined as described for the nose. Lungs of mice injected with PBS 
gave consistently luciferase background levels. 
4. Conclusions 
The transduction of basal cells or other progenitor cells in the airway epithelium with VSV-G 
pseudotyped LV vectors warrants further studies. A VSV-G pseudotyped last generation lentiviral 
vector can hold promise for long-term gene transfer into the respiratory epithelium and gene therapy of 
chronic lung diseases, such as cystic fibrosis.  
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